Trial Profile
Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs HSP Gp96 vaccine Cure and Sure Biotech (Primary)
- Indications Adenocarcinoma; Liver cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Cure&Sure Biotech
- 10 Dec 2015 Planned End Date changed from 1 Jul 2016 to 1 Nov 2019 as reported by ClinicalTrials.gov record.
- 10 Dec 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 10 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.